Market Closed -
OTC Markets
09:51:14 2024-05-15 am EDT
5-day change
1st Jan Change
0.75
USD
0.00%
-6.25%
+36.36%
Presentation Operator MessageOperator (Operator)Good day, ladies and gentlemen, and welcome to...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Nuo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Apr. 19
CI
Exor-backed NUO invests in Italian teenage clothing chain Subdued
Mar. 19
RE
Nuo Therapeutics, Inc. announced that it has received $0.9625 million in funding
Dec. 18
CI
Nuo Therapeutics, Inc. announced that it expects to receive $0.9625 million in funding
Dec. 07
CI
Nuo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 20
CI
Nuo Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-14
CI
Insider Buy: Nuo Therapeutics
23-08-04
MT
Nuo Therapeutics, Inc. announced that it has received $1.035 million in funding
23-07-31
CI
Nuo Therapeutics, Inc. announced that it expects to receive $1.035 million in funding
23-07-25
CI
Nuo Therapeutics Selects to Exhibit Aurix® System At Vizient Innovative Technology Exchange
23-06-26
CI
Nuo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-05-15
CI
Nuo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
23-04-17
CI
Nuo Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt
23-04-16
CI
Nuo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
22-11-04
CI
Nuo Therapeutics, Inc. announced that it expects to receive $0.5 million in funding from Pacific Medical, Inc.
22-08-23
CI
Nuo Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
22-08-08
CI
Nuo Therapeutics, Inc. Enters into an Exclusive Sales Agent and Services Agreement with Pacific Medical, Inc
22-06-28
CI
Nuo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
22-05-16
CI
Insider Buy: Nuo Therapeutics
22-05-02
MT
Nuo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
22-04-15
CI
Nuo Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt
22-04-14
CI
Nuo Therapeutics, Inc. announced that it expects to receive $3.55 million in funding
22-04-10
CI
Nuo Therapeutics, Inc. Announces Publication of Final Decision Memo for Autologous Blood Derived Products for Chronic Non-Healing Wounds by Centers for Medicare & Medicaid Services
21-04-20
CI
Nuo Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019
20-01-31
CI
Nuo Therapeutics, Inc. announced that it expects to receive $0.5 million in funding
19-11-14
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Nuo Therapeutics, Inc. is a commercial stage medical device company. The Company is focused on developing and marketing products for chronic wound care primarily within the United States. The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company's product, Aurix, is a biodynamic hematogel that uses a patient's own platelets and plasma as a catalyst for healing. Its commercial offering consists of point of care technology for the separation of autologous blood to produce a platelet-based therapy for the chronic wound care market. This offering is known as Aurix or the Aurix System. The Aurix System produces a platelet rich plasma (PRP) gel at the point of care using the patient's own platelets and plasma sourced from a small draw of peripheral blood. Aurix comprises a natural, endogenous complement of protein and non-protein signal molecules that contribute to effective healing.
More about the company
1st Jan change
Capi.
+36.36% 33.18M +7.52% 113B +11.38% 106B +0.90% 22.27B -12.64% 22.22B -4.41% 19.43B -37.85% 17.87B -8.58% 17.24B +7.77% 14.29B +37.41% 12.52B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**
#252525**/registration/member/**Blanc**1**7**To continue browsing, please register!**#ffffff50**14px**#33d251**